Free Trial

Tectonic Therapeutic Q1 2023 Earnings Report

Tectonic Therapeutic logo
$18.65 -0.26 (-1.37%)
As of 04:00 PM Eastern

Tectonic Therapeutic EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Tectonic Therapeutic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tectonic Therapeutic Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Tectonic Therapeutic Earnings Headlines

Analysts Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $77.75
Tectonic Therapeutic files to sell 3.69M shares of common stock for holders
Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Tectonic Therapeutic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tectonic Therapeutic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tectonic Therapeutic and other key companies, straight to your email.

About Tectonic Therapeutic

Tectonic Therapeutic (NASDAQ:TECX), Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

View Tectonic Therapeutic Profile

More Earnings Resources from MarketBeat